NEFECON Included in 2024 KDIGO Clinical Practice Guidelines

NEFECON Included in 2024 KDIGO Clinical Practice Guidelines

HONG KONG, Oct 2, 2024 – (ACN Newswire) – Recently, Everest Medicines has announced another positive development. The company’s lead product, NEFECON, as the only in-disease IgA nephropathy (IgAN) treatment, has been included in the “KDIGO 2024 Clinical Practice Guideline for the Management Of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)” (hereinafter referred to as the “New Guidelines (Draft)”…
Read More

Zaļā Josta - Reklāma